دورية أكاديمية
أعرض في EDS

Liver Resection after Downstaging Hepatocellular Carcinoma with Sorafenib

التفاصيل البيبلوغرافية
العنوان: Liver Resection after Downstaging Hepatocellular Carcinoma with Sorafenib
المؤلفون: L. Barbier, F. Muscari, S. Le Guellec, A. Pariente, P. Otal, B. Suc
المصدر: International Journal of Hepatology, Vol 2011 (2011)
بيانات النشر: Hindawi Limited, 2011.
سنة النشر: 2011
المجموعة: LCC:Diseases of the digestive system. Gastroenterology
مصطلحات موضوعية: Diseases of the digestive system. Gastroenterology, RC799-869
الوصف: Background. Sorafenib is a molecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma in Child A patients. Aims. To address the question of sorafenib as neoadjuvant treatment. Methods. We describe the cases of 2 patients who had surgery after sorafenib. Results. The patients had a large hepatocellular carcinoma in the right liver with venous neoplastic thrombi (1 in the right portal branch, 1 in the right hepatic vein). After 9 months of sorafenib, reassessment showed that tumours had decreased in size with a necrotic component. A right hepatectomy with thrombectomy was performed, and histopathology showed 35% to 60% necrosis. One patient had a recurrence after 6 months and had another liver resection; they are both recurrence-free since then. Conclusion. Sorafenib can downstage hepatocellular carcinoma and thus could represent a bridge to surgery. It may be possible to select patients in good general condition with partial regression of the tumour with sorafenib for a treatment in a curative intent.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2090-3448
2090-3456
Relation: https://doaj.org/toc/2090-3448; https://doaj.org/toc/2090-3456
DOI: 10.4061/2011/791013
URL الوصول: https://doaj.org/article/b0163a0fad234b8b81b206784a4de53e
رقم الأكسشن: edsdoj.b0163a0fad234b8b81b206784a4de53e
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:20903448
20903456
DOI:10.4061/2011/791013